Sometimes the science works and the stock doesn't care. That's roughly the story with CRISPR Therapeutics AG (CRSP) this week.

On Monday, the company presented clinical data showing that a single course of its investigational therapy CTX310 deeply reduced lipid levels in patients with severe hypertriglyceridemia. These results reinforce the therapy's potential to serve as a one-time gene editing treatment for this high-risk patient population.

The therapy uses in vivo CRISPR/Cas9 editing to target angiopoietin-like protein 3, or ANGPTL3. At Day 30, a single course produced a 65% mean reduction in circulating ANGPTL3 and a 63% mean drop in triglycerides among participants whose median baseline triglyceride levels exceeded 1,000 mg/dL. That is a lot of triglyceride. For context, normal is generally under 150 mg/dL.

Beyond Triglycerides: The Atherogenic Lipoprotein Story

The Phase 1b trial evaluated 10 patients with severe hypertriglyceridemia, each receiving a single-course treatment of CTX310. All 10 participants reached at least 30 days of follow-up as of the data cutoff.

Along with the triglyceride reductions, CTX310 generated substantial decreases across atherogenic lipoproteins. Participants achieved a 51% mean reduction in non-HDL-C and a 23% average drop in apolipoprotein B (ApoB). Patients also achieved a 16% mean decrease in LDL-C from a low mean baseline of 60 mg/dL.

In participants monitored for at least 90 days, the reductions in ANGPTL3 and triglycerides persisted over time. That durability matters for a one-shot therapy. If you are editing someone's DNA, you want the effect to stick around.

Notably, the study reported zero cases of acute pancreatitis, even though 30% of enrolled participants entered the trial with a history of the condition. Pancreatitis is one of the scarier complications of severely elevated triglycerides, so a goose egg there is a meaningful data point.

A Clean Safety Profile, Which Is Never a Given With Gene Editing

CTX310 proved well tolerated among study participants. Seven patients completed at least 90 days of safety monitoring as of the data cutoff date.

The trial recorded no serious adverse events related to CTX310 and no Grade 3 or higher treatment-related adverse complications. Furthermore, patients showed no clinically relevant elevations in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) liver enzymes. Liver signals are a classic worry with genetic medicines, so the absence of them is worth flagging.

One patient experienced a Grade 2 infusion-related reaction, which resolved and permitted the individual to complete the infusion. Not a showstopper.

CRISPR Therapeutics continues to advance CTX310 across multiple lipid disorders, with recruitment in additional Phase 1b cohorts actively ongoing.

The Analyst Take: Better Than Expected

William Blair on Monday wrote, "The Phase Ib CTX310 data at AHA came in ahead of our expectations, with the 63% triglyceride (TG) reduction at Day 30 comparing favorably with our roughly 50% expectation heading into the presentation."

Analyst Myles Minter added, "With RMAT designation granted for CTX310 in sHTG and for elevated LDL-C, we believe the dataset has preliminary regulatory buy-in and look forward to additional Phase Ib trial updates."

William Blair reiterates the Outperform rating on CRISPR shares.

CRSP Price Action: CRISPR Therapeutics shares were down 8.17% at $45.95 at the time of publication on Tuesday, according to market data.

So the data beat expectations, the safety profile looked clean, and the stock still sold off. Welcome to biotech, where the bar is always moving and the market has a habit of grading on a curve you didn't know existed.